Current Pilots
Funding Source | Principal Investigator Department | Funding Period | Project Title |
---|---|---|---|
CF RDP | James Bruce, PhD Medicine, Genome Sciences | 2024-26 | Investigation of the diagnostic potential of Pseudomonas aeruginosa protein levels in blood and urine |
CF RDP | Dustin Long, PhD Medicine, Anesthesiology | 2024-26 | Investigating P. aeruginosa mRNA transcripts as indicators of antibiotic efficacy |
NIH P30 CFRTC | Jarrad Scarlett, MD, PhD Pediatric Gastroenterology | 2022-24 | Role of dysfunctional gut-brain signaling in the pathogenesis of cystic fibrosis-related diabetes |
NIH P30 CFRTC | Patrick Mitchell, PhD Microbiology | 2022-24 | CFTR deficiency modulates epithelial inflammasomes |
NIH P30 CFRTC | Benjamin Freedman, PhD Nephrology | 2022-24 | Modeling CFTR function with human kidney organoids |
NIH P30 CFRTC | William Grady, MD Neel Dey, MD Clinical Research, Fred Hutch | 2022-24 | Colonic inflammation and dysbiosis: Factors that induce colorectal cancer (CRC) in cystic fibrosis |
CFF RDP | Alison Feder, PhD | 2022-24 | Evolutionary and mutational drivers of Pseudomonas aeruginosa persistence through Trikafta |
CFF RDP | Eric Morrell, MD | 2021-24 | Role of Soluble PD-L1 in Chronic Lung Allograft Dysfunction |
CFF RDP | Amy Willis, PhD | 2021-23 | Estimating the composition of the cystic fibrosis pulmonary microbiome |
CFF RDP | Waleed Abuzeid, MD Associate Professor, Otolaryngology | 2020-24 | Disruption of Pseudomonas aeruginosa biofilms using a novel nitric oxide-releasing nanoparticle |
NH P30 CFRTC | Edward Kelly, PhD Associate Professor, Pharmaceutics | 2020-24 | CF kidney phenotype and potential consequences in the era of CFTR correction |
NIH P30 CFRTC | Pavan Bhatraju, MD Acting Instructor, Pulmonary and Critical Care | 2018-23 | Identification of Predictive Biomarkers for Antibiotic Associated Nephrotoxicity in Cystic Fibrosis |